Ivonescimab, Chemotherapy, and SRS for Non-Small Cell Lung Cancer Brain Metastases
ClinicalTrials.gov Studies
Summary
The NIH National Library of Medicine registered a Phase 1 clinical trial (NCT07535463) on ClinicalTrials.gov testing ivonescimab in combination with standard chemotherapy and stereotactic radiosurgery for patients with non-small cell lung cancer that has spread to the brain. The study aims to establish the safe dosage of ivonescimab in this combination regimen and evaluate its effectiveness in treating brain metastases. The trial is listed as Phase 1, indicating an early-stage safety and dosing study.
What changed
ClinicalTrials.gov added a new Phase 1 trial registration (NCT07535463) for ivonescimab combined with chemotherapy and stereotactic radiosurgery in patients with non-small cell lung cancer and brain metastases. The trial will test different doses to find the optimal safe dose that causes few or mild side effects before evaluating treatment effectiveness.
Pharmaceutical sponsors conducting oncology research, clinical investigators, and healthcare providers involved in lung cancer treatment may reference this registry entry when tracking emerging combination therapy approaches. Researchers and investors in oncology drug development may use this record to monitor ivonescimab's clinical development trajectory.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
Phase 1 NCT07535463 Kind: PHASE1 Apr 17, 2026
Abstract
The researchers are doing this study to test the safety of ivonescimab given in combination with standard chemotherapy and stereotactic radiosurgery (SRS) in people with non-small cell lung cancer (NSCLC) that has spread to the brain (brain metastases). The researchers will test different doses of the study drug to find the best dose that causes few or mild side effects in participants. Once the dose is found, the researchers will test it in a new group of participants to see if it is effective in treating their NSCLC brain metastases.
Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab, Stereotactic Radiosurgery
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.